All News

Found 72,053 articles

• Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million

  9/27/2023

  Gritstone bio, Inc. announced that it was awarded a contract by the Biomedical Advanced Research and Development Authority to conduct a Phase 2b comparative study evaluating Gritstone’s self-amplifying mRNA vaccine candidate containing Spike plus other viral targets to protect against COVID-19.

• Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual MeetingFour-year Analysis of C-144-01 Trial Cohorts 2 and 4

  9/27/2023

  Iovance Biotherapeutics, Inc. announced poster presentations reporting clinical data and trial design for tumor infiltrating lymphocyte therapies at the Society for Immunotherapy of Cancer’s 38th Annual Meeting in San Diego, CA, November 1-5, 2023.

• Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer

  9/27/2023

  Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.

• Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases

  9/27/2023

  Precision BioSciences, Inc. today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 18/161,560, titled “Engineered Meganucleases That Target Human Mitochondrial Genomes.”

• VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern

  9/27/2023

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced interim data from the Phase 1 clinical study of its multivalent pan-coronavirus vaccine candidate, VBI-2901, which expresses the ancestral COVID-19, SARS, and MERS spike antigens.

• Therma Bright Announces Amendments to InStatin & InVixa Acquisitions

  9/27/2023

  InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)

• Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023

  9/27/2023

  Cidara Therapeutics, Inc. today announced that it will present new data on its drug-Fc conjugate (DFC) candidate, CD388, in an oral presentation and two poster presentations at IDWeek 2023.

• Akari Therapeutics to Present at Emerging Growth Conference

  9/27/2023

  Akari Therapeutics, Plc today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023.

• Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application

  9/27/2023

  Vaccinex, Inc today announced that it will present data on a new ActivMAb® application on September 28th and an update on the Phase 1b/2 pepinemab study in patients with PDAC on September 29th.

• Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

  9/27/2023

  Mainz Biomed N.V. announced today that it will present the positive detailed results from its ColoFuture study at the 4th International Conference on Gastroenterology which occurs on October 16th - 18th in Paris, France.

• Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

  9/27/2023

  Can-Fite BioPharma Ltd today announced that its study titled “Namodenoson Inhibits the Growth of Pancreatic Carcinoma via De-regulation of the Wnt/β-catenin Signaling Pathway” has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer, held from September 27-30, 2023, in Boston, Massachusetts.

• Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

  9/27/2023

  Coeptis Therapeutics Holdings, Inc. today announced that Colleen Delaney, MD, MSc, Chief Scientific and Medical Officer, will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.

• Pulmonary Fibrosis Foundation Announces PFF Summit 2023

  9/27/2023

  The Pulmonary Fibrosis Foundation (PFF) will present its biennial PFF Summit 2023 from Nov. 9-11 in Orlando, Fla. The three-day international conference, focused on pulmonary fibrosis (PF) and interstitial lung disease (ILD) research and education, will be held at the JW Marriott Orlando Grande Lakes.

• Coya Therapeutics to Present at the LD Micro Investor Conference

  9/27/2023

  Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Tregs, announces that management will present at the LD Micro Investor Conference in Los Angeles, CA on October 3 at 8:00am PT.

• Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

  9/26/2023

  Vaccinex, Inc., a clinical-stage biotechnology company will report on novel findings for its lead product, pepinemab, with implications for treatment of Alzheimer’s and other slowly progressive neurodegenerative diseases and for cancer immunotherapy at two upcoming Medical Conferences.

• The Pancreatic Cancer Action Network Selects Oncolytics Biotech® Inc. To Receive $5 Million Therapeutic Accelerator Award to Develop Leading-Edge Treatments

  9/26/2023

  In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network announced Oncolytics Biotech, Inc. as the recipient of its second annual PanCAN Therapeutic Accelerator Award.

• MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. ArmyR&D project budget increased to $6.5Million to advance NexoBrid as a non-surgical field care solution

  9/26/2023

  MediWound Ltd. announced that the U.S. Department of Defense, through the Medical Technology Enterprise Consortium, has awarded MediWound additional funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army.

• Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

  9/26/2023

  In a major achievement, Avalo Therapeutics proudly announces the payoff of the remainder of its $35 million debt owed to Horizon Technology Finance Corporation.

• Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

  9/26/2023

  Century Therapeutics announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.

• Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

  9/26/2023

  Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced encouraging preliminary safety, tolerability, pharmacokinetic and translational data from the initial two dose level cohorts (n=8) from Part 1 of its ongoing Phase 1/2 MYCHELANGELO™ I study evaluating OTX-2002 in patients with hepatocellular carcinoma (HCC) and other solid tumors associated with the c-MYC (MYC) gene.